希罗达联合奥沙利铂治疗老年晚期结直肠癌的疗效及安全性评价

李艳芳

（陕西省宝鸡市陈仓医院，陕西 宝鸡，721000）

浏览次数：114次 下载次数：357次

摘要：

目的 探讨希罗达联合奥沙利铂治疗老年晚期结直肠癌的临床疗效及安全性。方法 本次研究对象为2016年3月至2016年10月我院收治的100例老年晚期结直肠癌患者，按照随机数字表法分为观察组和对照组，每组50例。对照组采用希罗达治疗，观察组在希罗达治疗的基础上联合使用奥沙利铂。比较两组患者的临床治疗效果以及治疗期间的不良反应发生情况。结果 观察组患者的脱发、神经毒性、恶心、呕吐、皮肤色素沉着发生率与对照组比较，差异无统计学意义（P>0.05）；观察组患者的治疗总有效率为58.00%，显著高于对照组的30.00%，差异具有统计学意义（P<0.05）。结论 希罗达联合奥沙利铂治疗老 年晚期结直肠癌的临床疗效显著，不良反应少，安全性高，有助于提高癌症晚期患者的生活质量，此治疗方法可在临床推广 使用。

关键词：希罗达；奥沙利铂；老年晚期结直肠癌；安全性

中图分类号：R735.3文献标志码：A文章编号：2096-1413(2017)32-0036-02

Safety and efficacy evaluation of Xeloda combined with oxaliplatin in elderly patients with advanced colorectal cancer
LI Yan-fang
(Chencang Hospital of Baoji City, Baoji 721000, China)

ABSTRACT: Objective To explore the clinical efficacy and safety of Xeloda combined with oxaliplatin in elderly patients with advanced colorectal cancer. Methods A total of 100 cases of elderly patients with advanced colorectal cancer in our hospital from March 2016 to October 2016 were selected as the research objects. All the patients were randomly divided into observation group and control group according to random table method, with 50 cases in each group. The control group was treated with Xeloda, while the observation group was treated with oxaliplatin based on the use of Xeloda. The clinical efficacy and adverse reactions during the treatment were compared between the two groups. Results The incidence of alopecia, neurotoxicity, nausea, vomiting, skin pigmentation in the observation group were not significantly different from those in the control group(P>0.05). The total effective rate of observation group was 58.00%, which was higher than 30.00% of the control group, the difference was statistically significant (P<0.05). Conclusion Xeloda combined with oxaliplatin in the treatment of advanced colorectal cancer has significant clinical efficacy, with less adverse reaction, high safety, and it can improve the life quality of patients with advanced cancer, this treatment can be widely used in clinic.
KEYWORDS: xeloda; oxaliplatin; elderly patients with advanced colorectal cancer; safety

参考文献：
[1] 李大鹏,李仕武.奥沙利铂联合希罗达一线化学治疗K-ras 突变型结直肠癌的疗效分析[J].浙江临床医学,2016,18(4):626-627.
[2] 姜文翰.抗EGFR 单克隆抗体联合COX-2 抑制剂对人结直肠腺癌HT-29 细胞的放射增敏研究[D].郑州:郑州大学,2014.
[3] 弋振营,李宁,高岭,等.调强适形放射治疗联合替吉奥化学治疗直肠癌术后放疗后局部复发性直肠癌的临床疗效及安全性分析[J].转 化医学电子杂志,2015,2(6):26-27.
[4] 王跃辉,曲卓慧,秦英.破壁灵芝孢子粉联合希罗达联合奥沙利铂方案化疗治疗晚期结直肠癌的临床观察[J].中国实用医药,2014,9(21):108-109.
[5] 林菜梅,罗泽民,罗燕娜,等.顺铂联合希罗达方案与奥沙利铂联合希罗达方案治疗晚期胃癌的疗效分析[J].黑龙江医学,2015,39(4):431-432.
[6] 曾巍,屠宴会.奥沙利铂+5-氟尿嘧啶/希罗达联合西妥昔单抗或单纯化疗一线用于进展期大肠癌的疗效与KRAS 基因状态的关系[J]. 中国老年学杂志,2016,36(2):363-364.
[7] 田亚丽.替吉奥联合奥沙利铂治疗40 例晚期胃癌的临床疗效分 析[J].吉林医学,2014,35(6):1194.
[8] GRANDE C,QUINTERO G,CANDAMIO S,et al.Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer[J].J Geriatr Oncol,2013,4(2):114-121.
[9] 黄伶,郭俊华.益气化痰散结方联合XELOX化疗方案治疗晚期复发性结肠癌的临床研究[J].中华中医药学刊,2014,32(3):670-672.
[10] 张艳兵,屠洋洋,叶孙志,等.DOF 和DOX 方案治疗不可切除晚期胃癌的不良反应的对比分析[J].温州医科大学学报,2016,46(1):60-64.
[11] 周璇,卢敏,吴瀛达.奥沙利铂联合希罗达治疗晚期结直肠癌的临床观察[J].温州医科大学学报,2010,40(3):282-283.
[12] 丁令池,田思源,陆俊国,等.希罗达联合奥沙利铂治疗老年晚期结直肠癌的临床观察[J].肿瘤基础与临床,2012,25(5):380-382.
[13] 夏晓天,贾正飞.奥沙利铂联合希罗达用于结直肠癌术后患者的安全性及疗效观察[J].实用癌症杂志,2017,32(8):1331-1333.